Know Cancer

or
forgot password

Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Pain, Bone Metastasis

Thank you

Trial Information

Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis


PROTOCOL SCHEMA

Group A Treatment of single site of painful bone metastasis:

Arm 1: 4 Gy single fraction; mandate first retreatment if moderate or severe pain persists
or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after
initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or
severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm),
retreat with 8 Gy after > 4 weeks

Arm 2: 8 Gy single fraction, mandate first retreatment if moderate or severe pain persists
or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after
initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or
severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm),
retreat with 8 Gy after > 4 weeks

Group B Treatment of multiple bone metastasis: lower hemibody radiotherapy (LHBI):

Arm 3: 8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites
of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second
reirradiation with 8 Gy using local RT fields optional (at discretion of PI);

Arm 4: 12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a
minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or
recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation
with 8 Gy using local RT fields optional (at discretion of PI) ;


Inclusion Criteria:



- histological diagnosis of malignancy associated with radiological evidence of painful
bone metastasis

- If patients with two sites of pain requiring separate treatment are to be entered,
the same randomized treatment option will be used for both sites, but response at
each site will be scored and analyzed separately.

- age > 18 years

- anticipated remaining life of at least 12 weeks (3 months)

- informed consent

Exclusion Criteria:

- Primary histology myeloma

- Sites of previous RT or previous radioisotope treatment

- conditions or circumstances, which may interfere with treatment or follow-up

- complicated bone metastasis (pathological fractures, metastatic spinal cord
compression)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Pain Relief (response rate) at 4 weeks

Outcome Time Frame:

Up to 52 weeks

Safety Issue:

No

Principal Investigator

Branislav Jeremic, Md, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

International Atomic Energy Agency

Authority:

United Nations: International Atomic Energy Agency

Study ID:

E33028

NCT ID:

NCT00610272

Start Date:

January 2008

Completion Date:

January 2012

Related Keywords:

  • Pain
  • Bone Metastasis
  • single bone metastasis
  • multiple bone metastasis
  • pain relief
  • radiotherapy
  • Neoplasm Metastasis
  • Neoplasms, Second Primary
  • Bone Neoplasms
  • Bone Marrow Diseases

Name

Location